Wells Fargo analyst Derek Archila raised the firm’s price target on Ascendis Pharma to $289 from $264 and keeps an Overweight rating on the shares. The firm believes shares remain attractive given TransCon CNP’s win in ACH, as the company has potentially 3 drugs with over $1B-plus revenue opportunities. Focus will shift back to Yorvipath’s forthcoming U.S. launch, which Wells thinks will ramp well and offers upside for the stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Disney, DirecTV agree to restore programming, B+L mulls sale: Morning Buzz
- Morning Movers: Bausch + Lomb surges as said to consider potential sale
- Ascendis Pharma’s Growth Treatment Excels in Trial
- Ascendis Pharma Reports Positive Trial Results
- Ascendis Pharma announces data from ApproaCH trial of TransCon CNP